Vericel (VCEL) Other Non Operating Income (2010 - 2026)
Vericel (VCEL) posted Other Non Operating Income of -$22000.0 for Q2 2026, down 130.99% sequentially from $71000.0 in Q1 2026, and up 8.33% YoY from -$20307.7 in Q2 2025.
Powered by 
Analysis
Vericel (VCEL) Other Non Operating Income (2010 - 2026) Analysis & Trends
Vericel has reported Other Non Operating Income for 17 years, with the latest figure at -$22000.0 in Q2 2026.
- Quarterly Other Non Operating Income rose 8.33% year-over-year to -$22000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$13000.0 (down 105.7% YoY) and the FY2025 annual result came in at -$44000.0, down 122.56% from the prior year.
- Other Non Operating Income retreated to -$22000.0 in Q2 2026 per VCEL's latest filing, from $71000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $140000.0 in Q3 2024 and troughed at -$36000.0 in Q4 2025.
- A 5-year average of $19944.4 and a median of -$5000.0 in 2022 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income jumped 14100.0% in 2024, then plunged 200.0% in 2025.
- Over 5 years, Other Non Operating Income stood at -$3000.0 in 2022, then soared by 2833.33% to $82000.0 in 2023, then declined by 14.63% to $70000.0 in 2024, then slumped by 151.43% to -$36000.0 in 2025, then surged by 38.89% to -$22000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$22000.0, $71000.0, and -$36000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Vericel | 2.05 Bn | 1.88 Bn | 56.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -22,000.00 |
| Mar 31, 2026 | 71,000.00 |
| Dec 31, 2025 | -36,000.00 |
| Sep 30, 2025 | -26,000.00 |
| Jun 30, 2025 | -24,000.00 |
| Mar 31, 2025 | 42,000.00 |
| Dec 31, 2024 | 70,000.00 |
| Sep 30, 2024 | 140,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Mar 31, 2024 | -7,000.00 |
| Dec 31, 2023 | 82,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -5,000.00 |
| Mar 31, 2023 | -12,000.00 |
| Dec 31, 2022 | -3,000.00 |
| Sep 30, 2022 | -5,000.00 |
| Jun 30, 2022 | -9,000.00 |
| Mar 31, 2022 | 112,000.00 |
| Dec 31, 2021 | 8,000.00 |
| Sep 30, 2021 | -13,000.00 |